Journey Medical Corporation is a commercial-stage pharmaceutical company. Co. is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the U.S.. Its marketed products, which have been approved by the U.S. Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. We show 31 historical shares outstanding datapoints in our coverage of DERM's shares outstanding history.
Understanding the changing numbers of DERM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like DERM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching DERM by allowing them to research DERM shares outstanding history
as well as any other stock in our coverage universe. |
Free DERM Email Alerts:
Video: Shares Outstanding Importance
